Joseph E. Levitt

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

Jennifer G. Wilson, Kathleen D. Liu, Hanjing Zhuo et al. · The Lancet Respiratory Medicine · 2014 · 782 citations · Full text

Regenerative Medicine, Cell Therapy, Stem Cells +9

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Michael A. Matthay, Carolyn S. Calfee, Hanjing Zhuo et al. · The Lancet Respiratory Medicine · 2018 · 612 citations · Full text

Acute Lung Injury, Respiratory Distress Syndrome (Pulmonary Critical Care), Randomised Phase 2A +9

A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients*

Shannon S. Carson, John P. Kress, Jo E. Rodgers et al. · Critical Care Medicine · 2006 · 332 citations

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

Jennifer G. Wilson, Laura J. Simpson, Anne-Maud Ferreira et al. · JCI Insight · 2020 · 270 citations · Full text

Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States

Jennifer E. Flythe, Magdalene M. Assimon, Matthew J. Tugman et al. · American Journal of Kidney Diseases · 2020 · 231 citations · Full text

Hemodialysis, Intensive Care Units, Medicine +10